Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on April 24, 2014. The report announces the results of operations for the fiscal quarter ended March 31, 2014, and provides updated full-year guidance.
Key Financial Metrics and Guidance
The filing references a news release containing specific GAAP and non-GAAP financial measures for the quarter, but the text of this 8-K does not provide the specific numerical values for revenue, profit, cash flow, or margins for the quarter ended March 31, 2014. Instead, it outlines the following full-year fiscal 2014 guidance:
- Adjusted Diluted EPS: Expected range of $3.64 to $3.74 from continuing operations.
- Revenue Growth: Expected range of 30% to 34%.
- Adjusted Operating Income Growth: Expected range of 12% to 16%.
- Adjusted Operating Margin: Expected decline of 20 to 23 basis points.
- Free Cash Flow: Expected range of $500 million to $700 million.
- Capital Expenditures: Expected in the $300 million range.
- Share Repurchases: Expected spend of approximately $500 million, subject to market conditions.
Material Changes and Non-GAAP Adjustments
The Company utilizes non-GAAP financial measures to evaluate operating performance. Adjustments to diluted earnings per share from continuing operations include:
- Gains from antitrust litigation settlements.
- LIFO expense amounts.
- Acquisition-related intangibles amortization.
- Warrant expense and share dilution from unexercised warrants.
- Special employee severance, litigation, and other expenses.
Reconciliations of these non-GAAP measures to GAAP are provided in Exhibit 99.1, which is incorporated by reference but not detailed in this text.
Management Commentary and Risks
Management attributes the expected decline in adjusted operating margins to the onboarding of significant new lower-margin business and growth in the brand pharmaceutical business with large customers. The filing notes that share repurchase plans are subject to market conditions.
Investor Verification Checklist
- Verify the specific GAAP revenue, net income, and EPS figures for the quarter ended March 31, 2014, in the attached news release (Exhibit 99.1).
- Review the reconciliation table in Exhibit 99.1 to understand the magnitude of non-GAAP adjustments, particularly regarding antitrust litigation gains and LIFO expenses.
- Confirm the status of the $500 million share repurchase program and any subsequent market condition impacts.
- Assess the impact of the "lower margin business" on future profitability trends beyond the current fiscal year.